Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07868627). This is a study registration, not published results. Lead sponsor: Mclean Hospital. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 75 participants (ESTIMATED). Conditions: Depression, Anxiety, Trauma Patients. Interventions: DRUG: D-Cycloserine (DCS); DEVICE: Transcranial Magnetic Stimulation; BEHAVIORAL: Unified Protocol; BEHAVIORAL: Psychoeducation. Primary outcome measures: Patient Health Questionnaire 9 (PHQ-9) , At each study visit, measured at Baseline, and 1-week, 1-month, and 3-months after treatment; Generalized Anxiety Disorder-7 (GAD-7) , At each study visit, measured at baseline, 1-week, 1-month, and 3 months after treatment; Montgomery-Åsberg Depression Rating Scale (MADRS) , At each study visit, measured at baseline and 1-week, 1-month, and 3-months after treatment. Brief summary: This study is testing whether combining a rapid form of transcranial magnetic stimulation (TMS), an oral medication called d-cycloserine (DCS), and therapy can improve brain flexibility and emotional control in adults experiencing moderate-to-severe depression, anxiety, or trauma symptoms. TMS is a non-invasive treatment that uses gentle magnetic pulses to stimulate specific areas of the brain. In this phase of the study, all participants receive active accelerated TMS (delivering multiple brief sessions in a single day) along with DCS, a medication that helps enhance brain learning and plasticity. Participants will be randomly assigned to have TMS directed at one of two brain targets: a region called the precuneus (identified using personalized brain scans) or the dorsolateral prefrontal cortex (a standard area for mood treatment). Afterward, participants are randomly assigned to complete three weeks of either therapist-led talk therapy (a modified Unified Protocol) or self-guided educational videos and readings. The main goals are to determine which brain stimulation target works best and to see whether therapist-led therapy leads to more lasting symptom relief and brain changes compared to self-guided education.